Plain-English translation of NCT06469944 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , an immunotherapy drug, combined with standard chemotherapy treatments for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be surgically removed. Some participants will also receive an additional investigational drug called sacituzumab tirumotecan. The goal is to see whether these combinations help people live longer and control their cancer better than chemotherapy alone.
Currently, people with advanced gastric and esophageal cancers have limited treatment options. This trial is exploring whether adding immunotherapy to chemotherapy can improve outcomes for patients who have never been treated before, potentially offering a more effective approach than existing standard treatments.
You likely qualify if…
You likely don't qualify if…
Participants will receive intravenous infusions of the medication every 6 weeks for up to about 2 years, combined with chemotherapy given either by mouth or IV infusion according to their doctor's choice. You will have regular clinic visits for treatment, blood tests, and imaging scans to monitor how the cancer responds. The exact schedule depends on which chemotherapy regimen your doctor selects, but infusions typically occur every 2 to 3 weeks as part of the combined treatment plan.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States